West Pharmaceutical Services, Inc. (NYSE: WST) reported Q4 EPS of $0.59, $0.04 better than the analyst estimate of $0.55. Revenue for the quarter came in at $295.4 million versus the consensus estimate of $290.05 million.

West Pharmaceutical Services, Inc. sees FY2012 EPS of $2.37-$2.55, versus the consensus of $2.51.

For earnings history and earnings-related data on West Pharmaceutical Services, Inc. (WST) click here.

Earnings Guidance